Related Experiment Video
Updated: Aug 30, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status
Javier Octavio Mejía-Hernández1,2,3, Dinesh Raghu1,2,3,4, Franco Caramia1,2,3
1Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia.
Abstract:
Metastatic prostate cancer is a lethal disease in patients incapable of responding to therapeutic interventions. Invasive prostate cancer spread is caused by failure of the normal anti-cancer defense systems that are controlled by the tumour suppressor protein, p53. Upon mutation, p53 malfunctions. Therapeutic strategies to directly re-empower the growth-restrictive capacities of p53 in cancers have largely been unsuccessful, frequently because of a failure to discriminate responses in diseased and healthy tissues. Our studies sought alternative prostate cancer drivers, intending to uncover new treatment targets. We discovered the oncogenic potency of MDM4 in prostate cancer cells, both in the presence and absence of p53 and also its mutation. We uncovered that sustained depletion of MDM4 is growth inhibitory in prostate cancer cells, involving either apoptosis or senescence, depending on the cell and genetic context. We identified that the potency of MDM4 targeting could be potentiated in prostate cancers with mutant p53 through the addition of a first-in-class small molecule drug that was selected as a p53 reactivator and has the capacity to elevate oxidative stress in cancer cells to drive their death.
Insights
Targeting MDM4 shows promise for treating metastatic prostate cancer. Combining MDM4 inhibition with a p53 reactivator drug may enhance treatment efficacy, especially in tumors with mutated p53.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Metastatic prostate cancer is a lethal disease often resistant to therapy.
- The tumor suppressor protein p53 is crucial for anti-cancer defenses but often malfunctions upon mutation.
- Current p53-targeting therapies face challenges in selectively targeting cancer cells.
Purpose of the Study:
- To identify novel therapeutic targets for prostate cancer.
- To investigate the role of MDM4 in prostate cancer growth and survival.
- To explore combination strategies for treating prostate cancer with mutant p53.
Main Methods:
- Investigated the oncogenic role of MDM4 in prostate cancer cells.
- Assessed the effects of MDM4 depletion on cancer cell growth, apoptosis, and senescence.
- Evaluated the efficacy of combining MDM4 targeting with a p53 reactivator drug.
Main Results:
- MDM4 was found to be oncogenic in prostate cancer cells, irrespective of p53 status.
- Sustained MDM4 depletion inhibited prostate cancer cell growth through apoptosis or senescence.
- Combining MDM4 targeting with a p53 reactivator drug potentiated anti-cancer effects in mutant p53 prostate cancers.
Conclusions:
- MDM4 is a viable therapeutic target for prostate cancer.
- Targeting MDM4, particularly in combination with p53 reactivators, offers a promising strategy for treating advanced prostate cancer, including cases with p53 mutations.
Related Concept Videos
02:23Abnormal Proliferation
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:34Inhibition of Cdk Activity